Apoptosis in cancer: from pathogenesis to discovery of advanced selective Bcl-2 family inhibitors
| Autor: | Samaa Abbas, Nermin S. Abdou, Deena S. Lasheen, Dalal A. Abou El Ella |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Archives of Pharmaceutical Sciences Ain Shams University, Vol 3, Iss 1, Pp 37-54 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2356-8380 2356-8399 |
| DOI: | 10.21608/aps.2019.20225 |
| Popis: | Cancer is a genetic disease characterized by two features: unregulated cell growth and tissue invasion (metastasis). It can be viewed as the result of a succession of genetic changes during which a normal cell is transformed into a malignant one. Evasion of cell death, apoptosis, is one of the essential changes in a cell that cause this malignant transformation. Hence, reduced apoptosis or its resistance plays a vital role in carcinogenesis. The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway. Disease states arise upon deregulation of the Bcl-2 family of proteins, where cell death is either promoted or evaded; one of the most common tactic cancer cells utilize to promote survival is anti-apoptotic protein overexpression. Specifically, Bcl-2 overexpression has been shown to be a major chemoresistance factor in a number of human cancers, and for this reason, Bcl-2 targeting is a pharmacologic priority in the quest to reactivate cell death for therapeutic benefit in cancer. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|